Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Integrating Depression Services Into DM Management
Integrating Depression Services Into Type 2 Diabetes Mellitus Management
Status: Archived
Hospital of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Integrating Depression Services Into DM Management
Integrating Depression Services Into Type 2 Diabetes Mellitus Management
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
492
mi
from 43215
Birmingham, AL
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
492
mi
from 43215
Birmingham, AL
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
186
mi
from 43215
Jeffersonville, IN
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
186
mi
from 43215
Jeffersonville, IN
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
163
mi
from 43215
Detroit, MI
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
163
mi
from 43215
Detroit, MI
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
78
mi
from 43215
Lima, OH
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
78
mi
from 43215
Lima, OH
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
793
mi
from 43215
Ponca City, OK
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
793
mi
from 43215
Ponca City, OK
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
2060
mi
from 43215
Medford, OR
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2060
mi
from 43215
Medford, OR
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
525
mi
from 43215
Charleston, SC
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
525
mi
from 43215
Charleston, SC
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ (MSDC-0160) in Type 2 Diabetic Patients
A Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazoneâ„¢ in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
1667
mi
from 43215
Peoria, AZ
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1667
mi
from 43215
Peoria, AZ
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
622
mi
from 43215
Little Rock, AR
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
622
mi
from 43215
Little Rock, AR
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
620
mi
from 43215
Kansas City, KA
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
620
mi
from 43215
Kansas City, KA
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
643
mi
from 43215
Boston, MA
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
643
mi
from 43215
Boston, MA
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
1751
mi
from 43215
Henderson, NV
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1751
mi
from 43215
Henderson, NV
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
1333
mi
from 43215
Albuquerque, NM
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1333
mi
from 43215
Albuquerque, NM
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
348
mi
from 43215
Charlotte, NC
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
348
mi
from 43215
Charlotte, NC
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
1006
mi
from 43215
Bismarck, ND
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1006
mi
from 43215
Bismarck, ND
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
78
mi
from 43215
Lima, OH
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
78
mi
from 43215
Lima, OH
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
525
mi
from 43215
Charleston, SC
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
525
mi
from 43215
Charleston, SC
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Clinical Trial Facility
2006
mi
from 43215
Mountlake Terrace, WA
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2006
mi
from 43215
Mountlake Terrace, WA
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
622
mi
from 43215
Little Rock, AR
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
622
mi
from 43215
Little Rock, AR
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
1162
mi
from 43215
Denver, CO
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1162
mi
from 43215
Denver, CO
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
436
mi
from 43215
Atlanta, GA
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
186
mi
from 43215
Jeffersonville, IN
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
186
mi
from 43215
Jeffersonville, IN
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
405
mi
from 43215
Bettendorf, IA
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
405
mi
from 43215
Bettendorf, IA
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
620
mi
from 43215
Kansas City, KA
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
620
mi
from 43215
Kansas City, KA
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
188
mi
from 43215
Louisville, KY
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
188
mi
from 43215
Louisville, KY
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
809
mi
from 43215
Ellsworth, ME
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
809
mi
from 43215
Ellsworth, ME
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
163
mi
from 43215
Detroit, MI
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
163
mi
from 43215
Detroit, MI
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
662
mi
from 43215
Jackson, MS
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
662
mi
from 43215
Jackson, MS
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
394
mi
from 43215
St Louis, MO
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
394
mi
from 43215
St Louis, MO
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
1751
mi
from 43215
Henderson, NV
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1751
mi
from 43215
Henderson, NV
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
464
mi
from 43215
West Orange, NJ
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
464
mi
from 43215
West Orange, NJ
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
515
mi
from 43215
Albany, NY
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
515
mi
from 43215
Albany, NY
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
348
mi
from 43215
Charlotte, NC
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
348
mi
from 43215
Charlotte, NC
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
78
mi
from 43215
Lima, OH
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
78
mi
from 43215
Lima, OH
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
2060
mi
from 43215
Medford, OR
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2060
mi
from 43215
Medford, OR
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Clinical Trial Facility
416
mi
from 43215
Philadelphia, PA
The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
416
mi
from 43215
Philadelphia, PA